Oja, Marek, juhendajaTamm, Sirli, juhendajaMägi, GreteTartu Ülikool. Loodus- ja täppisteaduste valdkondTartu Ülikool. Arvutiteaduse instituut2024-10-022024-10-022024https://hdl.handle.net/10062/105026This study investigated the usage of interacting drug pairs with potential bleeding risk and the occurrence of bleeding diagnoses in patients who used these drug combinations. Specifically, it examined which drug pairs were used, how the usage trends of these ingredient pairs changed over time, the number of bleeding diagnoses received, and which ingredient pairs were involved. The data used in the study were sourced from three databases: the Health Insurance Fund Prescription Center (prescribed and dispensed medications), the claims data repository, and the Health Information System (discharge summaries and referral responses). The dataset included a random sample of 10% of all individuals in Estonia with a national ID number (n=150 824) and their health data from 2012–2019. Medications were purchased by 138,572 persons during this period. The results of the study showed that 14,901 patients (10,8% of all patients who purchased medications) used drug pairs associated with a bleeding risk, of which 651 received a bleeding diagnosis (4,4% of patients). Among the 651 patients who experienced bleeding, there were 2847 bleeding episodes. Bleeding was most frequently associated with the use of drug pairs involving warfarin combined with torsemide, omeprazole, and allopurinol. The average age at the time of the first bleeding episode was 72,1 years (SD ±12,5), and the risk of bleeding was higher in men. Age is a significant factor in the occurrence of bleeding, with the majority of bleeding events occurring in the 60+ age group.etAttribution-NonCommercial-NoDerivs 3.0 Estoniakoostoimet omavad ravimidretsepti andmedveritsuse diagnoosiddrug-drug interaction (DDI)prescription datableeding diagnosesmagistritöödinformaatikainfotehnoloogiainformaticsinfotechnologyThesis